<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H1B644A5F58E1449E88BD928E00F22D98" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 1672 IH: Maintaining Investments in New Innovation Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-02-27</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1672</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250227">February 27, 2025</action-date><action-desc><sponsor name-id="D000230">Mr. Davis of North Carolina</sponsor> (for himself, <cosponsor name-id="J000302">Mr. Joyce of Pennsylvania</cosponsor>, <cosponsor name-id="G000583">Mr. Gottheimer</cosponsor>, <cosponsor name-id="T000478">Ms. Tenney</cosponsor>, <cosponsor name-id="Y000067">Mr. Yakym</cosponsor>, <cosponsor name-id="M001206">Mr. Morelle</cosponsor>, <cosponsor name-id="H001067">Mr. Hudson</cosponsor>, <cosponsor name-id="B001314">Mr. Bean of Florida</cosponsor>, <cosponsor name-id="M001215">Mrs. Miller-Meeks</cosponsor>, <cosponsor name-id="A000372">Mr. Allen</cosponsor>, <cosponsor name-id="V000134">Ms. Van Duyne</cosponsor>, <cosponsor name-id="P000608">Mr. Peters</cosponsor>, <cosponsor name-id="M001213">Mr. Moore of Utah</cosponsor>, and <cosponsor name-id="C001120">Mr. Crenshaw</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XI of the Social Security Act to protect access to genetically targeted technologies.</official-title></form><legis-body id="H8C8E1B5A4761430CB13036C6C0C9F1F4" style="OLC"><section id="H89BC80CC7738492C83115A7901EEC680" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Maintaining Investments in New Innovation Act</short-title></quote>.</text></section><section id="H3AB6BCE18C9040DEB03B5AC69EA4579A"><enum>2.</enum><header>Amendment to definition of qualifying single source drug</header><text display-inline="no-display-inline">Section 1192(e) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1320f-1">42 U.S.C. 1320f–1(e)</external-xref>) is amended—</text><paragraph id="H56C5349CFA6D480D854610B9C0B2C621"><enum>(1)</enum><text>in paragraph (1)(A)(ii), by inserting <quote>(or, in the case of an advanced drug product (as defined in paragraph (4)), 11 years)</quote> after <quote>7 years</quote>; and</text></paragraph><paragraph id="H8C9E2EC807344809B7349EB82E725BDB"><enum>(2)</enum><text>by adding at the end the following new paragraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HCC081E8D04F84AACA802BA2FBCF9F3E4"><paragraph id="H60FA1C9E3A16474787EDB5B23B3C0165"><enum>(4)</enum><header>Advanced drug product defined</header><text>For purposes of paragraph (1)(A)(ii), the term <term>advanced drug product</term> means a drug that incorporates or utilizes a genetically targeted technology (as defined in section 529A(c)(2) of the Federal Food, Drug, and Cosmetic Act) that may result in the modulation (including suppression, up-regulation, or activation) of the function of a gene or its associated gene product.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section></legis-body></bill> 

